Ravulizumab Significantly Reduces Relapses in NMOSD Trial
The phase 3 CHAMPION-NMOSD trial evaluated ravulizumab-cwvz, a C5 complement inhibitor, in 58 adults with AQP4 Ab+ NMOSD.
The phase 3 CHAMPION-NMOSD trial evaluated ravulizumab-cwvz, a C5 complement inhibitor, in 58 adults with AQP4 Ab+ NMOSD.
Feeling like ‘in a fog’ and sadness may predict symptoms lasting 28 days or longer following a sport-related concussion
SPN-830 provides a continuous subcutaneous infusion of apomorphine through an infusion pump.
The recalled lots of Levetiracetam Injection 500mg per 5mL; NDC Number 25021-780-05, were distributed nationwide from March to November 2021.
Eprontia is approved for the treatment of partial-onset or primary generalized tonic-clonic seizures and migraine prevention.
History of TBI tied to 52 percent increased odds of prescription opioid use, 65 percent increased odds of prescription opioid misuse
The system works with Medtronic’s Percept™ PC Neurostimulator.
Using the programmer app, clinicians are able to remotely prescribe new treatment settings to the patient’s neuromodulation device via cloud and Bluetooth-based technology.
The test measures glial fibrillary acidic protein and ubiquitin carboxyl-terminal hydrolase L1, biomarkers present in blood plasma at elevated concentrations after a brain injury.
The NDA for SPN-830 is supported by data from an extensive development program that includes the phase 3 TOLEDO study and a supportive open-label study.